glp-1 receptor agonist and dpp-4 inhibitor combination contraindicated versus kidney and cardiovascular outcomes in clinical practice in type-2 diabetes Table 2 from DPP- 4
Description
In this review we have explored the link between GLP-1, inflammation, and sepsis
Perceptions of barriers to effective obesity care: results from the national ACTION study
Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats
Vascular biology of glucagon receptor superfamily peptides: mechanistic and clinical relevance
